Global Drug Discovery Technologies Industry

Global Drug Discovery Technologies Industry

  • February 2022 •
  • 486 pages •
  • Report ID: 5817664 •
  • Format: PDF

What`s New for 2022?
-Global competitiveness and key competitor percentage market shares
-Market presence across multiple geographies - Strong/Active/Niche/Trivial
-Online interactive peer-to-peer collaborative bespoke updates
-Access to our digital archives and MarketGlass Research Platform
-Complimentary updates for one year

Global Drug Discovery Technologies Market to Reach $80.2 Billion by 2026

Drug discovery assists in discovering new medications by using a broad range of technologies that are used for research and the introduction of new drugs. Extensive usage of therapeutics in different diseases created the requirement in drug discovery. Several techniques like RNA and nanotechnology interference are being utilized for drug discovery, in turn generating opportunities for the manufacturers of drug discovery technology in new segments. The COVID-19 pandemic caused a temporary break in drug discovery clinical trials of many diseases because the researchers, healthcare sector, and academia concentrated on stopping the spread of coronavirus. However, the pandemic`s impact led to the invention and adoption of new working ways, which paved a path for future clinical trials. Clinical trial physicians and sponsors are highly flexible in administering virtual study and acquiring the study data remotely utilizing modern medical wearables. The new advancements are simplifying the complicated procedures and overcoming the lack of required onsite professionals. The drug discovery market is anticipated to gain an advantage by adopting technological advancements together with the biotechnology and pharmaceutical sectors. Amid the COVID-19 crisis, the global market for Drug Discovery Technologies estimated at US$53.3 Billion in the year 2021, is projected to reach a revised size of US$80.2 Billion by 2026, growing at a CAGR of 8.1% over the analysis period. Small Molecule Drugs, one of the segments analyzed in the report, is projected to grow at a 7.8% CAGR to reach US$60.2 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Biologics segment is readjusted to a revised 8.8% CAGR for the next 7-year period. This segment currently accounts for a 23.9% share of the global Drug Discovery Technologies market.

Growth in the market is majorly driven by the growing geriatric population worldwide and people above 60 years of age are highly susceptible to chronic illnesses. The efficient drug demand from increasing affluent patients is yet another factor propelling the drug discovery global market. Furthermore, the advancements in molecular biology, biotechnology, genomics, and nanotechnology paved a path for increasing investments in drug discovery. Additionally, many blockbuster drugs` patent expiries are anticipated to make a profitable market for the existent players. Healthcare organizations worldwide are seeking drug discovery opportunities, which have been previously done using active ingredient identification from conventional remedies. It is important to discover advanced, efficient, and new drugs to fight illnesses, as there is an increase in many life-threatening illnesses and the inception of various health-related problems. The drug discovery recently has evolved significantly with technologies like NMR, mass spectrometry, chemotherapy, microplate readers, RANi, proteomics, gel electrophoresis, microfluidics, nucleic acid and protein isolation, nanotechnology, and protein and DNA microarrays. Thus, drug discovery process has become highly accurate, more refined, and less time-consuming.

Pharmaceutical organizations that are new, too, have the opportunity to launch into the drug discovery global market through generics. Pharmaceutical companies are primarily focusing on the technologies of drug development because drug discovery has a critical role to play in the cycle of drug development. However, drug development and discovery require a colossal investment and are time taking, which causes low-profit margins for pharmaceuticals. Pharmaceutical manufacturers generally face an increase in expiring patents of developed drugs, intensifying the negative impact of the research cycle`s long duration. HTS or high-throughput screening is an extensively utilized drug discovery technology, using which a huge quantity of possible biological modulators are analyzed against a defined target set. HTS technology allows biologically relevant compounds` rapid portfolio building and HTS technological advancements like multidetector readers, reliable automation, pattern and database recognition software, and imaging software and hardware are anticipated to lead the HTS technology usage. Drug discovery technologies have a huge role to play in the pharmaceutical sector`s overall growth, as the technologies immensely contribute to the innovative and blockbuster drugs` easy initiation. Diverse illnesses like CVD, cancer, and CNS disorders like Alzheimer`s and Parkinson`s generated adequate opportunities in the drug discovery technologies market.

The U.S. Market is Estimated at $16.4 Billion in 2021, While China is Forecast to Reach $12.7 Billion by 2026

The Drug Discovery Technologies market in the U.S. is estimated at US$16.4 Billion in the year 2021. The country currently accounts for a 31.12% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$12.7 Billion by the year 2026 trailing a CAGR of 10.1% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.3% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.9% CAGR.

The rise in late-stage drug failure rates is driving the demand for drug delivery technologies. The average cost of drug development has doubled in recent years to reach over US$2.6 billion. By therapeutic area, oncology and immuno-modulatory drugs are the most expensive to develop. While oncology treatment continues to dominate the existing and future drug pipelines, R&D investments on metabolic disorders, cardiovascular diseases, and respiratory diseases is gaining strength in recent years. As oncology trials require specific trial design expertise, the likelihood of attrition rates tends to be high. As new drug development is focused on the need to target many smaller subsets of indications, clinical trials are conducted on smaller patient population. A smaller market to recover R&D costs, reimbursement issues, and pushback on high drug costs further increase the average cost of drug development. Despite the scientific, technological, and operational advances in R&D aimed at increasing the efficiency and success of drug development process, a significant number of clinical trials still fail. As the early phase of clinical trials are exploratory, failure at this stage is expected to a certain extent. Failure represents the highest cost of the overall cost of drug development. Clinical trial failures may also arise when the body of knowledge about a disease or condition is limited, particularly rare diseases. Also, the rollout of more complex and extensive clinical trials is another critical factor increasing the late-stage failure rates. The cost of failed clinical trials is high, and the burden placed on ways to reduce the continuously high failure rate provides impetus for drug discovery technologies market.

Select Competitors (Total 129 Featured) -
  • Affymetrix Inc.
  • Agilent Technologies, Inc.
  • Curia Global, Inc.
  • Astrazeneca plc
  • Bayer Healthcare AG
  • Bio-Rad Laboratories Inc.
  • Charles River Laboratories International Inc.
  • Evotec Ag
  • Illumina, Inc.
  • Luminex Corporation
  • Merck KGaA
  • Molecular Discovery Ltd.
  • Novartis AG
  • Thermo Fisher Scientific Inc.